Tacrolimus Exposure and Mycophenolate Pharmacokinetics and Pharmacodynamics Early After Liver Transplantation

被引:2
|
作者
Saeves, Ingjerd [1 ,2 ]
Line, Pal-Dag [3 ]
Bremer, Sara [1 ]
Vethe, Nils T. [1 ]
Tveit, Ragnhild G. [1 ]
Meltevik, Tore J. [1 ]
Bergan, Stein [2 ,4 ]
机构
[1] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
[2] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway
[3] Oslo Univ Hosp, Dept Transplantat Med, Oslo, Norway
[4] Oslo Univ Hosp, Dept Pharmacol, Oslo, Norway
关键词
tacrolimus; mycophenolic acid; inosine monophosphate dehydrogenase; IMPDH; liver transplantation; therapeutic drug monitoring; RESISTANCE-ASSOCIATED PROTEIN-2; P-GLYCOPROTEIN; CLINICAL PHARMACOKINETICS; ACID GLUCURONIDE; MOFETIL; POLYMORPHISMS; DEHYDROGENASE; CYCLOSPORINE; EXPRESSION; RECIPIENTS;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Mycophenolic acid (MPA) and tacrolimus play important roles in immunosuppressive therapy after solid organ transplantation (Tx) and show large intra- and interindividual pharmacokinetic (PK) variabilities. The purpose of this study was to describe the intra-and interindividual variabilities of MPA and tacrolimus PKs during the first 3 weeks after adult liver transplantation. Furthermore, inosine monophosphate dehydrogenase activity was investigated. Materials: This study describes PK and pharmacodynamic parameters of MPA and the PKs of tacrolimus in 16 liver transplant recipients, in 4 follow-up periods (I-IV). Results: The area under the concentration-time curve (AUC(0-12 hours)) for tacrolimus was low early after Tx (eg, median 78.6 around day 4) and variable in all 4 periods ranging from 3.8 to 267 mu g h/L, whereas the predose concentrations (C-0) were 0.0-17.9 mu g/L. From periods I to IV, the tacrolimus dose was doubled and the median dose per body weight-adjusted AUC(0-12 hours) increased by 123% (P = 0.017). The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C-0 was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L). The maximum inhibition of inosine monophosphate dehydrogenase within a dose interval ranged from 9.5% to 100%. Conclusions: This study confirmed the large variability in the PKs of tacrolimus and MPA in liver transplant recipients. In particular, the MPA AUC(0-12 hours) was consistently low in all 4 periods. We also observed a low tacrolimus exposure during the first days after transplant compared with the following weeks.
引用
收藏
页码:46 / 53
页数:8
相关论文
共 50 条
  • [21] Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation
    Rodriguez-Peralvarez, Manuel
    Colmenero, Jordi
    Gonzalez, Antonio
    Gastaca, Mikel
    Curell, Anna
    Caballero-Marcos, Aranzazu
    Sanchez-Martinez, Ana
    Di Maira, Tommaso
    Ignacio Herrero, Jose
    Almohalla, Carolina
    Lorente, Sara
    Cuadrado-Lavin, Antonio
    Pascual, Sonia
    Angeles Lopez-Garrido, Maria
    Gonzalez-Grande, Rocio
    Gomez-Orellana, Antonio
    Alejandre, Rafael
    Zamora-Olaya, Javier
    Bernal-Bellido, Carmen
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (06) : 1671 - 1682
  • [22] Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation
    Guy-Viterbo, V.
    Scohy, A.
    Verbeeck, R. K.
    Reding, R.
    Wallemacq, P.
    Musuamba, Flora Tshinanu
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (08) : 1533 - 1542
  • [23] Comparison of Pharmacokinetics and Pharmacogenetics of Once- and Twice-Daily Tacrolimus in the Early Stage After Renal Transplantation
    Niioka, Takenori
    Satoh, Shigeru
    Kagaya, Hideaki
    Numakura, Kazuyuki
    Inoue, Takamitsu
    Saito, Mitsuru
    Narita, Shintaro
    Tsuchiya, Norihiko
    Habuchi, Tomonori
    Miura, Masatomo
    TRANSPLANTATION, 2012, 94 (10) : 1013 - 1019
  • [24] Tacrolimus and mycophenolate mofetil as first line immunosuppression after lung transplantation
    Neurohr, Claus
    Huppmann, Patrick
    Zimmermann, Gregor
    Leuchte, Hanno
    Baumgartner, Rainer
    Hatz, Rudolf
    Frey, Lorenz
    Ueberfuhr, Peter
    Bittmann, Iris
    Behr, Juergen
    Reichart, Bruno
    TRANSPLANT INTERNATIONAL, 2009, 22 (06) : 635 - 643
  • [25] Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study
    Kim, Deok Gie
    Kim, Sung Hwa
    Hwang, Shin
    Hong, Suk Kyun
    Ryu, Je Ho
    Kim, Bong-Wan
    You, Young Kyoung
    Choi, Donglak
    Kim, Dong-Sik
    Nah, Yang Won
    Cho, Jai Young
    Kim, Tae-Seok
    Hong, Geun
    Joo, Dong Jin
    Kim, Myoung Soo
    Kim, Jong Man
    Lee, Jae Geun
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (10)
  • [26] Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan® and Mowel® after liver transplantation
    Vollmar, Johanna
    Bellmann, Maren Christina
    Darstein, Felix
    Hoppe-Lotichius, Maria
    Mittler, Jens
    Heise, Michael
    Ruettger, Bernd
    Weyer, Veronika
    Zimmermann, Anca
    Lang, Hauke
    Galle, Peter R.
    Zimmermann, Tim
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6139 - 6149
  • [27] Relative carcinogenicity of tacrolimus vs mycophenolate after solid organ transplantation and its implications for liver transplant care
    Liu, Dorothy
    Youssef, Mark M.
    Grace, Josephine A.
    Sinclair, Marie
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04) : 650 - 660
  • [28] Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
    Christine E. Staatz
    Susan E. Tett
    Clinical Pharmacokinetics, 2004, 43 : 623 - 653
  • [29] Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation
    Sikma, Maaike A.
    Hunault, Claudine C.
    Huitema, Alwin D. R.
    De Lange, Dylan W.
    Van Maarseveen, Erik M.
    CLINICAL PHARMACOKINETICS, 2020, 59 (04) : 403 - 408
  • [30] Tacrolimus exposure early after lung transplantation and exploratory associations with acute cellular rejection
    Darley, David R.
    Carlos, Lilibeth
    Hennig, Stefanie
    Liu, Zhixin
    Day, Richard
    Glanville, Allan R.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (07) : 879 - 888